Jacob Taylor*
Monoclonal antibody-based immunotherapy has evolved into a pivotal component of cancer treatment, standing alongside surgery, radiation, and chemotherapy. With a diverse array of clinically relevant mechanisms of action, monoclonal antibodies not only directly target tumor cells but also stimulate enduring anti-tumor immune responses. The multifaceted properties of antibodies as a therapeutic platform have spurred the development of novel cancer treatment strategies, significantly impacting cancer care. This review delves into the established mechanisms of action, current clinical applications for cancer treatment, and the mechanisms of resistance associated with monoclonal antibody therapy. Additionally, it explores the shift in monoclonal antibody-based strategies towards augmenting anti-tumor immune responses by targeting immune cells rather than solely focusing on tumor antigens, along with an examination of ongoing combination therapies.
English 
Spanish 
Chinese 
Russian 
French 
Japanese 
Portuguese 
Hindi